LENZ Therapeutics (LENZ) Asset Utilization Ratio (2025 - 2026)

LENZ Therapeutics' (LENZ) quarterly Asset Utilization Ratio came in at 0.02 in Q1 2026, up 23.27% on a QoQ basis from 0.02 in Q4 2025.

LENZ Therapeutics (LENZ) Asset Utilization Ratio (2025 - 2026) Analysis & Trends

LENZ Therapeutics (LENZ) has 2 years of Asset Utilization Ratio data on file, last reported at 0.02 in Q1 2026.

On a quarterly basis, Asset Utilization Ratio changed N/A year-over-year to 0.02 in Q1 2026; TTM through Mar 2026 was 0.02, a N/A change from a year earlier, with the FY2025 full-year figure at 0.02, changed N/A from the prior year.
Asset Utilization Ratio for Q1 2026 stood at 0.02, up from 0.02 in the prior quarter.
Over the last five years, Asset Utilization Ratio for LENZ reached as high as 0.08 in Q3 2025 and fell as low as 0.02 in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Asset Util. (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	0.69
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	0.47
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	0.37
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	LENZ Therapeutics	158.34 Mn	158.34 Mn	825,000.00	0.02

Download Data